Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS

Hayato Akimoto; Akio Negishi; Shinji Oshima; Haruna Wakiyama; Mitsuyoshi Okita; Norimitsu Horii; Naoko Inoue; Shigeru Ohshima; Daisuke Kobayashi

doi:10.1177/1533317519899546

Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS

Hayato Akimoto, Akio Negishi, Shinji Oshima, Haruna Wakiyama, Mitsuyoshi Okita, Norimitsu Horii, Naoko Inoue, Shigeru Ohshima, Daisuke Kobayashi

Josai University

Research output: Contribution to journal › Article › peer-review

47 Citations (Scopus)

Abstract

Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; P <.001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; P <.001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; P <.001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; P =.014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; P =.011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.

Original language	English
Journal	American Journal of Alzheimer's Disease and other Dementias
Volume	35
DOIs	https://doi.org/10.1177/1533317519899546
Publication status	Published - 2020
Externally published	Yes

Keywords

Alzheimer disease
FDA adverse event reporting system
antidiabetics
dementia
type 2 diabetes mellitus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/1533317519899546

Cite this

@article{25fb67a497234943af8c9499ebf3a0f6,

title = "Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS",

abstract = "Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; P <.001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; P <.001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; P <.001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; P =.014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; P =.011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.",

keywords = "Alzheimer disease, FDA adverse event reporting system, antidiabetics, dementia, type 2 diabetes mellitus",

author = "Hayato Akimoto and Akio Negishi and Shinji Oshima and Haruna Wakiyama and Mitsuyoshi Okita and Norimitsu Horii and Naoko Inoue and Shigeru Ohshima and Daisuke Kobayashi",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2020.",

year = "2020",

doi = "10.1177/1533317519899546",

language = "English",

volume = "35",

journal = "American Journal of Alzheimer's Disease and other Dementias",

issn = "1533-3175",

publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS

AU - Akimoto, Hayato

AU - Negishi, Akio

AU - Oshima, Shinji

AU - Wakiyama, Haruna

AU - Okita, Mitsuyoshi

AU - Horii, Norimitsu

AU - Inoue, Naoko

AU - Ohshima, Shigeru

AU - Kobayashi, Daisuke

N1 - Publisher Copyright: © The Author(s) 2020.

PY - 2020

Y1 - 2020

N2 - Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; P <.001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; P <.001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; P <.001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; P =.014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; P =.011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.

AB - Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; P <.001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; P <.001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; P <.001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; P =.014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; P =.011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.

KW - Alzheimer disease

KW - FDA adverse event reporting system

KW - antidiabetics

KW - dementia

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85081920454&partnerID=8YFLogxK

U2 - 10.1177/1533317519899546

DO - 10.1177/1533317519899546

M3 - Article

C2 - 32162525

AN - SCOPUS:85081920454

SN - 1533-3175

VL - 35

JO - American Journal of Alzheimer's Disease and other Dementias

JF - American Journal of Alzheimer's Disease and other Dementias

ER -

Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this